Immunomedics — Proxy Contest (January 2017)
28 slides from Immunomedics's proxy contest presentation, Jan 18, 2017
Slide 1: R&D Day Presentation: Commercial Assessment and Competitive Landscape
Health Advances LLC BOSTON | SAN FRANCISCO | ZUG www.healthadvances.com R&D Day Presentation Commercial Assessment and Competitive Landscape Presented to January 18, 2017
Slide 2: Health Advances Disclaimer
2 R&D Day Presentation January 18, 2017 Health Advances Disclaimer Health Advances makes no representation or warranty, express or implied, as to the accuracy or completeness of any information contained in this document provided by the Client or by any third party, or that is based on such informat
Slide 3: Summary of IMMU-132 Commercial Potential
• Superior efficacy in late line therapy compared to current standards of care in all indications tested: triple negative breast cancer (TNBC), urothelial bladder cancer (UBC), small cell lung cancer (SCLC), and non - small cell lung cancer (NSCLC) • KOLs enthusiastic about IMMU - 132’s potential ap
Slide 4: Revenue by indication: initial launch and label expansion
Indication Initial Launch (MM) Label Expansion Monotherapy (MM) Label Expansion Combination with I/O (MM) TNBC US: $830 EU: $420 • 3L monotherapy after lines of chemotherapy and I/O therapy US: $1,220 EU: $600 • 2L monotherapy for BRCA, AR and IO biomarker positives • 1L monotherapy for IO biomarker
Slide 5: Peak US Revenues by Indication
IMMU - 132 Peak US Revenues by Indication IMMU - 132 could achieve ~$2B in peak US revenue in its lead indication of TNBC and over ~$5.4B across four tumor types. * US patients (2025) only. Note: Assumes annual US base price of $148,000 in 2016 dollars grown at 2.5% CAGR through 2025. Net revenues a
Slide 6: Initial Position Revenue Projections
$256 $674 $836 $1,085 $1,123 $1,1 6 1 $1,201 $1,242 $1,284 $1,328 $1,373 $1,4 2 0 $1,467 $154 $341 $590 $811 $973 $1,045 $1,092 $1,104 $1,116 $1,128 $1,140 $339 $409 $542 $557 $573 $588 $605 $621 $638 $656 $165 $197 $259 $262 $264 $267 $270 $273 $276 $279 $256 $674 $1,158 [ VA L U E [ ] VA L U E $1,
Slide 7: Agenda
Agenda R&D Day Presentation January 18, 2017 7 • TNBC • UBC • NSCLC • SCLC
Slide 8: TNBC initial position as 3L therapy
IMMU - 132 is expected to initially enter the market as a 3L therapy behind immunotherapies, targeted therapies, and taxanes, where applicable. IMMU - 132 Initial Position Metastatic TNBC TN BC BRCA Positive (~20%) AR* Positive (~15%) IO Biomarker Positive (~20%) IMMU - 132 CPI* +/ - Chemotherapy 1
Slide 9: TNBC comparative efficacy
IMMU - 132’s initial data in TNBC shows superior efficacy to current late line chemotherapies like eribulin and appears similar to front - line chemotherapies. IMMU - 132 Comparative Efficacy 29% 9% 34% 0% 20% 40% IM M U - 1 3 2 (6L) E r i b u l in (5L) P a c l it a x e l (1L) Overall Response Rate
Slide 10: TNBC monotherapy upside scenario
As a monotherapy, IMMU - 132 has the potential to be used before any currently available chemotherapies. IMMU - 132 Monotherapy Upside Scenario Metastatic TNBC TN BC BRCA Positive (~20%) AR* Positive (~15%) IO Biomarker Positive (~20%) IMMU - 132 PARP Inhibitor +/ - Chemotherapy CPI* +/ - Chemothera
Slide 11: TNBC combination upside scenario
IMMU - 132 could potentially be combined with a checkpoint inhibitor and a PARP inhibitor to become a first line option for most patients. IMMU - 132 Combination Upside Scenario Metastatic TNBC TN BC BRCA Positive (~20%) AR* Positive (~15%) IO Biomarker Positive (~20%) C h e moth e rapy PARP Inhibit
Slide 12: TNBC Revenue Projections: US + EU
12 Revenue Projections: US + EU Successful immuno - oncology and PARP inhibitor combinations would maximize potential 2018 - 2030 revenue at ~$25.7B. TNBC Revenue Forecast 2018 - 2030 Combination Revenue: US: ~$18.0B, EU: ~$7.7B, Total: ~$25.7B Note: Each revenue bar represents the additional achiev
Slide 13: Agenda
Agenda R&D Day Presentation January 18, 2017 13 • TNBC • UBC • NSCLC • SCLC
Slide 14: UBC Model Scenario: Initial Position
Model Scenario: Initial Position If successful, IMMU - 132 will begin as a third - line option for all patients following treatment with one line of immunotherapy and one line of chemotherapy. Source: Health Advances interviews and analysis, UpToDate 2016 Bladder Cancer Treatment, Karakiemicz PI 200
Slide 15: UBC comparative efficacy
IMMU - 132’s initial data in UBC shows superior efficacy to current 3L chemotherapies like paclitaxel and appears similar to front - line chemotherapies. IMMU - 132 Comparative Efficacy 36% 9% 15% 41% 0% 20% 40% 60% IM M U - 1 3 2 (3L) P a c l it a x e l (2L) At e zo l i zu ma b * Carb o - g e m (2L
Slide 16: UBC Model Scenario: Monotherapy Upside Position
Model Scenario: Monotherapy Upside Position As a monotherapy, IMMU - 132 could supplant the 2L chemotherapy regimens used in patients who cannot tolerate cisplatin. Atezolizumab or Other IO IO/IO or IO/ C h e mo ~5 0 % ~5 0 % Cisplatin Eligible Cisplatin Ineligible C is p lat i n R e g imen Metastat
Slide 17: UBC Model Scenario: Combination Upside Position
Model Scenario: Combination Upside Position A successful combination with a checkpoint inhibitor could make IMMU - 132 a first - line option for all metastatic urothelial bladder cancer patients. ~5 0 % ~5 0 % Cisplatin Eligible Cisplatin Ineligible Metastat i c UBC Targeted Options Cytotoxic Only I
Slide 18: UBC Revenue Projections: US + EU
18 $339 $409 $542 $557 $573 $588 $605 $621 $638 $656 [ VA L UE ] $106 $187 $262 $322 $351 $374 $384 $394 $103 $229 $396 $546 $660 $718 $760 $781 $803 $112 $339 $559 $876 $1,140 $1,381 $1,570 $1,674 $1,755 $1,804 $1,853 $0 $ 5 00 $ 1 ,0 0 0 $ 1 , 5 0 0 $112 2 0 20 2 0 21 2 0 22 2 0 23 2 0 24 2 0 25 2
Slide 19: Agenda
Agenda R&D Day Presentation January 18, 2017 19 • TNBC • UBC • NSCLC • SCLC
Slide 20: NSCLC Model Scenario: Initial Position
IMMU - 132 IMMU - 132 will be initially positioned behind a line of chemotherapy and a line of checkpoint inhibitor therapy, but will face strong competition for 3L and 4L patients. Model Scenario: Initial Position Note: Penetration in 3L and 4L will depend on the strength of data generated in pivot
Slide 21: NSCLC comparative efficacy
IMMU - 132’s initial clinical data is comparable to current chemotherapies; however, it is generated in sicker, later - line patients. IMMU - 132 Comparative Efficacy 19% 23% 20% 0% 20% 40% I MM U - 132 (4L) R am u ci r u mab/ Docetaxel (2L) N i v ol u ma b * (2L) Response Rate Selected Current and
Slide 22: NSCLC Model Scenario: Combination Label Expansion
IMMU - 132 in combination with a checkpoint inhibitor could become a first - line option for biomarker negative patients who cannot tolerate PD - X/CTLA - 4 combination therapy. Model Scenario: Combination Label Expansion Note: Penetration into each line of therapy will depend on forthcoming data ge
Slide 23: NSCLC Revenue Projections: US + EU
23 $154 $341 $590 $8 1 1 $973 $1, 0 45 $1, 0 92 $1, 1 04 $1, 1 16 $1, 1 28 $1, 1 40 [ V A L U E] $646 $1, 1 27 $1, 5 60 $1, 8 84 $2, 0 28 $2, 1 23 $2, 1 46 $2, 1 69 $879 $1,457 $2,100 $2,605 $2,976 $3,132 $3,240 $3,275 $3,310 $0 $ 5 00 $ 1 , 0 0 0 $ 1 , 5 0 0 $ 2 , 0 0 0 $ 2 , 5 0 0 $ 3 , 0 0 0 $ 3
Slide 24: Agenda
Agenda R&D Day Presentation January 18, 2017 24 • TNBC • UBC • NSCLC • SCLC
Slide 25: SCLC Model Scenario: Initial Position
Due to the probable approval of immunotherapies, IMMU - 132 would likely enter as a 3L treatment option. Model Scenario: Initial Position Source: Health Advances analysis; UpToDate, NCI SEER. S C LC Targeted Options Cytotoxic Only IO Options IMMU - 132 Position P lat i n u m Doublet Checkpoint Inhib
Slide 26: SCLC comparative efficacy
IMMU - 132’s initial data in SCLC shows good response rates and strong overall survival in the difficult - to - treat 3L population. IMMU - 132 Comparative Efficacy 16% 24% 38% [ V A L U E] 0% 25% 50% IM M U - 1 3 2 (3L) To p o t e ca n (2L) ROV A - T (2L/3L DLL3+) I p i l i mumab / Ni voluma b* (2L
Slide 27: SCLC Model Scenario: Combination Label Expansion
When combined with a checkpoint inhibitor or a platinum agent, IMMU - 132 may become a potent first - line option for metastatic SCLC patients. Model Scenario: Combination Label Expansion Note: Label expansion assumes successful checkpoint inhibitor combination or replacing etoposide in current 1L p
Slide 28: SCLC Revenue Projections: US + EU
28 $0 $ 5 00 $ 1 , 0 0 0 Net Re v enue ( U SD MM ) 1L Combination Incremental Revenue Initial Position $352 [ VA L U E ] $600 $341 $850 $588 $1,069 $805 $1,232 $964 $1,304 $1,034 $1,353 $1,080 $1,368 $1,092 $1,382 $1,103 $165 $197 $259 $262 $264 $267 $270 $273 $276 $279 $56 2020 2021 2022 2023 2024